Clinical Topics
Video
Focus on preventing comorbidities in MS, physician urges
NASHVILLE, TENN. – It’s a kind of ‘lifestyle disease’ since other conditions can worsen it, Dr. Allen C. Bowling says, so healthier living is...
Video
New guidelines for gadolinium-based contrast agents take conservative stance
NASHVILLE, TENN. – The agents remain necessary in initial diagnosis and other specific clinical scenarios.
Video
VIDEO: PML prevention is possible, even when treating patients with aggressive MS
NASHVILLE, TENN. – Short treatment periods with natalizumab are possible for patients with aggressive disease, even with JC virus antibody...
Conference Coverage
Value of alemtuzumab demonstrated in RRMS patients with prior IFNB-1a treatment
CARE-MS II extension data suggest that alemtuzumab provides a unique treatment approach for relapsing-remitting multiple sclerosis patients with...
Video
Pediatric MS gets a win with fingolimod
NASHVILLE, TENN. – First successful phase 3 study in pediatric MS may lead to a reshaping of the pediatric MS treatment paradigm.
Video
Inside the complex, surprising world of MS comorbidities
Research suggests some conditions are more common in MS. Cancer is an outlier: Its rates may actually be lower than in the general population.
Video
iPad app puts cognitive screening in the hands of MS patients
The Multiple Sclerosis Performance Test app attempts to sidestep the problem of time and manpower in administering cognitive screening.
Conference Coverage
Ocrelizumab safety update: Encouraging rates of serious infection, malignancy
No new safety signals were seen in the latest update from studies and postmarketing surveillance of MS patients treated with ocrelizumab.
Conference Coverage
Interferon treatment does not increase stroke risk in MS
Pooled data from 17 trials, as well as postmarketing surveillance data, show no increase in stroke risk with interferon treatment in MS patients...
Conference Coverage
EVOLVE-MS-1 study: ALKS 8700 shows promise for RRMS
LOS ANGELES – ALKS 8700, a novel prodrug of monomethyl fumarate, looks promising as an oral, disease-modifying treatment for RRMS.
